SEC
VERA icon

Seven Eight Capital’s Vera Therapeutics VERA Stock Holding History

Seven Eight Capital’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,243
Closed -$334K – 961
2024
Q2 		$334K Sell
9,243
-52,725
-85% -$2.09M 0.03% 589
2024
Q1 		$2.67M Buy
+61,968
New +$2.21M 0.28% 104

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Seven Eight Capital's VERA Position: Q3 2024 in Review

Seven Eight Capital sold out of Vera Therapeutics (VERA) in Q3 2024, closing a stake of 9,243 shares — an estimated $334K sold.

Seven Eight Capital first reported a position in VERA in Q1 2024 and held it in 2 quarters. The position peaked at $2.67M in Q1 2024. 173 funds tracked by Wall St. Rank hold VERA as of Q3 2024.

  • Seven Eight Capital reported no remaining Vera Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Seven Eight Capital sold 9,243 Vera Therapeutics shares in Q3 2024, an estimated $334K.
  • Seven Eight Capital first reported a position in Vera Therapeutics in Q1 2024 and held it in 2 quarters.
  • Seven Eight Capital's Vera Therapeutics position peaked at $2.67M in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.